The study evaluated the efficacy and safety of abrocitinib, a JAK1 inhibitor, in the treatment of chronic actinic dermatitis (CAD) in 16 patients over 3 months. After 12 weeks of treatment, there was a significant reduction in disease severity scores in all patients. No serious adverse events were reported during treatment. Analysis of plasma from 6 patients before and after treatment using the Olink proteomic panel revealed significant changes in inflammatory factors such as EN-RAGE, MCP-3, MCP-4, IL-13, CCL4, FGF21 and TNFRSF9. IL-13 and CCL-4 were identified as the main effective factors after treatment. Abrocitinib appears to be an effective therapeutic option for patients with CAD.